Cleared Traditional

K921464 - CAT.#40100, 40102, 40104 & 40106 YANKAUER SUCT INT (FDA 510(k) Clearance)

Class I General & Plastic Surgery device.

K921464 · Trinity Laboratories, Inc. · General & Plastic Surgery device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
May 1992
Decision
39d
Days
Class 1
Risk

K921464 is an FDA 510(k) clearance for the CAT.#40100, 40102, 40104 & 40106 YANKAUER SUCT INT. Classified as Catheter, Continuous Irrigation (product code GBQ), Class I - General Controls.

Submitted by Trinity Laboratories, Inc. (Salisbury, US). The FDA issued a Cleared decision on May 5, 1992 after a review of 39 days - a notably fast clearance cycle.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.4200 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Trinity Laboratories, Inc. devices

Submission Details

510(k) Number K921464 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 27, 1992
Decision Date May 05, 1992
Days to Decision 39 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary Statement
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
75d faster than avg
Panel avg: 114d · This submission: 39d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code GBQ Catheter, Continuous Irrigation
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 878.4200
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.